Registry for patients with advanced rare cancers in Asia
Official title: A Prospective Clinical Registry Study of Genetic Profiling and Targeted Therapies in Patients With Rare Cancers in ASIA
Run by National Cancer Center, Japan · NCT05217407 · Data updated 2026-11-12
This study is collecting information from patients with advanced rare cancers in Asia to see how different treatments work and to find better, personalized options for their care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | National Cancer Center, Japan Government |
| Locations | 18 sites (Chuo-ku, Tokyo and 17 other locations) |
| Status | Recruiting |
| Started | November 30, 2021 |
| Main results expected | March 31, 2027 |
| Study ends | March 31, 2030 |
| Registry record updated | March 22, 2024 |
| Trial ID | NCT05217407 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with a histological diagnosis of rare cancer or advanced-stage cancer.
✕Probably not a fit
Patients with cognitive impairments or those not diagnosed with rare cancers may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational registry study aims to collect comprehensive data from patients diagnosed with advanced-stage rare cancers in the Asia-Pacific region. It will gather clinical information, treatment details, prognosis, pathological diagnoses, and genetic biomarkers through next-generation sequencing. The study seeks to explore the relationships between different cancer types, treatment effects, and the incidence of genomic alterations to identify more effective, tailored treatment options for these rare malignancies.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for patients with rare cancers.
How similar studies have gone: Other studies focusing on genomic alterations in rare cancers have shown promise, suggesting that this approach could yield valuable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with a histological diagnosis of rare cancer, cancer of unknown primary origin, or cancer of rare tissue subtypes of common cancers. (Defined in protocol.) 2. Patients with Advanced stage cancer. Exclusion Criteria: 1\. Patients with complications of cognitive impairment.
Where it's running
-
National Cancer Center Hospital, Japan
Chuo-ku, Tokyo, Japan Recruiting -
Hospital Sultan Ismail
Johor Bahru, Johor, Malaysia Recruiting -
Hospital Pulau Pinang
Pulau Pinang, Pulau Pinang, Malaysia Recruiting -
Sarawak General Hospital
Kuching, Sarawak, Malaysia Recruiting -
Hospital Kuala Lumpur
Kuala Lumpur, Malaysia Recruiting -
University Malaya Medical Center
Kuala Lumpur, Malaysia Recruiting
Show 12 more locations
-
Institut Kanser negara
Putrajaya, Malaysia Recruiting -
St. Luke's Medical Center
Manila, Philippines Recruiting -
National Cancer Center Korea
Seoul, South Korea Recruiting -
National Taiwan University Hospital
Taipei, Zhongzheng, Taiwan Recruiting -
Taipei Veterans General Hospital
Taipei, Taiwan Recruiting -
Mahidol University by Faculty of Medicine, Ramathibodi Hospita
Bangkok, Thailand Recruiting -
Mahidol University by Faculty of Medicine, Siriraj Hospital
Bangkok, Thailand Recruiting -
Faculty of Medicine, Prince of Songkla University
Hat Yai, Thailand Recruiting -
Khon Kaen University by Faculty of Medicine, Srinagarind Hospital
Khon Kaen, Thailand Recruiting -
National Cancer Vietnam
Hanoi, Vietnam Recruiting -
Maharaj Nakorn Chiang Mai Hospital
Chiang Mai, Thailand Not yet recruiting -
Ho Chi Minh City Oncology Hospital
Ho Chi Minh City, Vietnam Not yet recruiting
Study contacts
- Principal investigator: Noboru Yamamoro, MD, PhD — National Cancer Center Hospital, Japan
- Study coordinator: Chiharu Mizoguchi, MD
- Email: ncch2007_office@ml.res.ncc.go.jp
- Phone: +81-(0)3-3542-2511
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Collecting data on rare and complex tumors in the thoraco-abdominal region
This study is collecting information on rare and complex tumors in the chest and abdomen to better understand how they are diagnosed, treated, and followed up over time.
-
Targeted therapy for rare cancers
This study is testing whether a personalized cancer treatment based on specific gene changes can help people with rare and hard-to-treat cancers feel better and improve their outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.